Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

US-based Sagent Pharma Raises $40 Million from China

publication date: Apr 12, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sagent Pharmaceuticals of Schaumberg, Illinois raised $40 million in two tranches of a series B financing from China sources. Zhejiang Hisun Pharmaceutical invested $10 million, which we reported earlier, and the remaining $30 million was contributed by an unnamed China-focused private equity investment fund. Sagent is building a large portfolio of generic injectable products that are “high quality, low cost,” using a global network of partners. More details...

Stock Symbol: (SHA: 600267)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...